CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Demark-Wahnefried, W.
Right arrow Articles by Walther, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demark-Wahnefried, W.
Right arrow Articles by Walther, P. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 9, 325-328, March 2000
© 2000 American Association for Cancer Research


Short Communications

Early Onset Baldness and Prostate Cancer Risk1

Wendy Demark-Wahnefried2, Joellen M. Schildkraut, Denis Thompson, Samuel M. Lesko, Lauren McIntyre, Pamela Schwingl, David F. Paulson, Cary N. Robertson, E. Everett Anderson and Philip J. Walther

Division of Urology/Duke University Medical Center, Durham, North Carolina 27710 [W. D-W., D. F. P., C. N. R., E. E. A., P. J. W.]; Program of Cancer Prevention, Detection and Control Research/Duke University Medical Center, Durham, North Carolina 27710 [J. M. S., D. T.]; School of Public Health, Boston University School of Medicine, Boston, Massachusetts 02146 [S. M. L.]; Purdue University, West Lafayette, Indiana 47907 [L. M.]; and Family Health International, Research Triangle Park, North Carolina 27713 [P. S.]

Prostatic carcinoma is the leading cancer among American men, yet few risk factors have been established. Although increased androgen levels have long been associated with both prostatic carcinoma and baldness, to date no studies have shown an association between hair patterning and prostate cancer risk. A lack of standardized instruments to assess baldness or the assessment of hair patterning during uninformative periods of time may have precluded the ability of previous studies to detect an association. We hypothesized that baldness, specifically vertex baldness, should be assessed using standardized instruments and during early adulthood if an association with prostate cancer risk is to be found. To test this hypothesis, we included identical items related to hair patterning in surveys that were administered in two distinct prostate cancer case-control studies (Duke-based study, n = 149; 78 cases; 71 controls and community-based study, n = 130; 56 cases; 74 controls). In each, participants were provided with an illustration of the Hamilton Scale of Baldness and asked to select the diagrams that best represented their hair patterning at age 30 and again at age 40. From these data, the following five categories were created and compared: not bald (referent group); vertex bald early onset (by age 30); vertex bald later onset (by age 40); frontal bald early onset (by age 30); frontal bald later onset (by age 40); and frontal (at age 30) to vertex bald (at age 40). Separate analyses of the two studies are consistent and suggest an association between vertex baldness and prostate cancer {vertex bald early onset odds ratios, 2.44 [confidence interval (CI), 0.57–10.46)] and 2.11 (CI, 0.66–6.73), respectively; vertex bald later onset odds ratios, 2.10 (CI, 0.63–7.00) and 1.37 (CI, 0.47–4.06), respectively}. Although statistical significance was not achieved in either one of these studies, the concordance between the data suggests a need for future studies to determine whether early onset vertex baldness serves as a novel biomarker for prostate cancer and whether androgen production, metabolism, or receptor status differs among these men when compared to those who exhibit other types of hair patterning.




This article has been cited by other articles:


Home page
Occup. Environ. Med.Home page
L Fritschi, D C Glass, J S Tabrizi, J E Leavy, and G L Ambrosini
Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia
Occup. Environ. Med., January 1, 2007; 64(1): 60 - 65.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. G. Giles, G. Severi, R. Sinclair, D. R. English, M. R. E. McCredie, W. Johnson, P. Boyle, and J. L. Hopper
Androgenetic Alopecia and Prostate Cancer: Findings from an Australian Case-Control Study
Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 549 - 553.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
W. Demark-Wahnefried, J. M. Schildkraut, E. Hawk, B. I. Graubard, and R. A. Breslow
Correspondence re: E. Hawk, et al., Male Pattern Baldness and Clinical Prostate Cancer in the Epidemiologic Follow-Up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000
Cancer Epidemiol. Biomarkers Prev., April 1, 2001; 10(4): 415 - 416.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.